Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.

Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):45-50. doi: 10.1016/j.atherosclerosissup.2012.10.004.

PMID:
23357140
2.

Actual situation of lipoprotein apheresis in Saxony in 2013.

Emmrich U, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:215-25. doi: 10.1016/j.atherosclerosissup.2015.02.034.

PMID:
25936329
3.

Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.

von Dryander M, Fischer S, Passauer J, Müller G, Bornstein SR, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):39-44. doi: 10.1016/j.atherosclerosissup.2012.10.005.

PMID:
23357139
4.

Lipoprotein apheresis--more than just cholesterol reduction?

Neumann CL, Schulz EG, Hagenah GC, Platzer U, Wieland E, Schettler V.

Atheroscler Suppl. 2013 Jan;14(1):29-32. doi: 10.1016/j.atherosclerosissup.2012.10.017. Review.

PMID:
23357137
5.

Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.

Groß E, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:226-32. doi: 10.1016/j.atherosclerosissup.2015.02.033.

PMID:
25936330
6.

Current situation of lipoprotein apheresis in Saxony.

Julius U, Taseva K, Fischer S, Passauer J, Bornstein SR.

Atheroscler Suppl. 2013 Jan;14(1):51-5. doi: 10.1016/j.atherosclerosissup.2012.10.003.

PMID:
23357141
7.

Lipoprotein apheresis: state of the art and novelties.

Stefanutti C, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):19-27. doi: 10.1016/j.atherosclerosissup.2012.10.021. Review.

PMID:
23357136
8.

Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.

Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.

Atheroscler Suppl. 2015 May;18:154-62. doi: 10.1016/j.atherosclerosissup.2015.02.013.

PMID:
25936320
9.

Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.

Klingel R, Heibges A, Fassbender C.

Atheroscler Suppl. 2015 May;18:35-40. doi: 10.1016/j.atherosclerosissup.2015.02.012.

PMID:
25936302
10.

Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.

Schampera S, Fischer S, Weiss N, Julius U.

Atheroscler Suppl. 2015 May;18:209-14. doi: 10.1016/j.atherosclerosissup.2015.02.031.

PMID:
25936328
11.

Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.

Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R; Pro(a)LiFe Study Group*.

Circulation. 2013 Dec 17;128(24):2567-76. doi: 10.1161/CIRCULATIONAHA.113.002432. Epub 2013 Sep 20.

12.

The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.

Sampietro T, Sbrana F, Bigazzi F, Ripoli A, Dal Pino B, Pasanisi EM, Petersen C, Coceani M, Luciani R, Pianelli M.

Atheroscler Suppl. 2015 May;18:268-72. doi: 10.1016/j.atherosclerosissup.2015.02.040.

PMID:
25936336
13.

Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.

Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:45-52. doi: 10.1016/j.atherosclerosissup.2015.02.007.

PMID:
25936304
14.

Current standards in diagnosis and therapy of hyperlipoproteinemia.

Fischer S, Schatz U, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):15-8. doi: 10.1016/j.atherosclerosissup.2012.10.035. Review.

PMID:
23357135
15.

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.

Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.

Clin Res Cardiol Suppl. 2015 Apr;10:8-13. doi: 10.1007/s11789-015-0071-3.

16.

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A; Scientific Board of GLAR for the German Apheresis Working Group.

Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):44-49. doi: 10.1007/s11789-017-0089-9. Erratum in: Clin Res Cardiol Suppl. 2017 Jul 17;:.

17.

Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.

Lamounier-Zepter V, Look C, Ehrhart-Bornstein M, Bornstein SR, Fischer S, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):129-34. doi: 10.1016/j.atherosclerosissup.2012.10.010.

PMID:
23357154
18.

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.

Heigl F, Hettich R, Mauch E, Klingel R, Fassbender C.

Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):50-54. doi: 10.1007/s11789-017-0081-4.

19.

First data from the German Lipoprotein Apheresis Registry (GLAR).

Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Ramlow W, Blume H; Scientific Board of GLAR for the German Apheresis Working Group.

Atheroscler Suppl. 2015 May;18:41-4. doi: 10.1016/j.atherosclerosissup.2015.02.006.

PMID:
25936303
20.

Homocysteine in lipoprotein apheresis patients--retrospective data analysis in apheresis center of a university hospital.

Tselmin S, Rodionov RN, Müller G, Bornstein S, Julius U.

Atheroscler Suppl. 2013 Jan;14(1):123-8. doi: 10.1016/j.atherosclerosissup.2012.10.011.

PMID:
23357153

Supplemental Content

Support Center